The effect of omega3 supplementation on plasma Peroxisome proliferator-activated receptors( ppar?) in obesity

INTERVENTION: Intervention 1: Intervention group: 2 omega3 capsula with 1 gr weight(containing 360 mg EPA and 240 mg DHA). Intervention 2: Pacebo group: 2 placebo capsula (containing paraffin). Intervention group: 2 omega3 capsula with 1 gr weight(containing 360 mg EPA and 240 mg DHA) Pacebo group: 2 placebo capsula (containing paraffin) Treatment ‐ Drugs CONDITION: Obesity due to excess calories Obesity. ; Obesity due to excess calories PRIMARY OUTCOME: Plasma PPARgamma. Timepoint: Baseline and at the end of intervention. Method of measurement: ELISA. SECONDARY OUTCOME: Appetite level. Timepoint: Baseline and at the end of intervention. Method of measurement: Visual analog scale questionnaire. Body composition. Timepoint: Baseline and at the end of intervention. Method of measurement: Bioelectrical Impedance. Food habits. Timepoint: Baseline and at the end of intervention. Method of measurement: Food Frequency Questionnaire. Thyroid hormons. Timepoint: Baseline and at the end of intervention. Method of measurement: ELISA. INCLUSION CRITERIA: INCLUSION CRITERIA: BMI>30, and age 18‐45 yrs. Exclusion criteria: Pregnancy and lactation, menopause, medical history of diabetes mellitus, liver, kidney and thyroid disorders. HIV disease. Any interfering medication with lipid profile. Receiving beta blocker medications. Omega3 or vitamin A supplementation, weight lowering drugs or special diet in the past 2 months and smoking.